Search Results - "Carney, Jennifer F."

Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast Cancer by Chavez-MacGregor, Mariana, Miao, Jieling, Pusztai, Lajos, Goetz, Matthew P, Rastogi, Priya, Ganz, Patricia A, Mamounas, Eleftherios P, Paik, Soonmyung, Bandos, Hanna, Razaq, Wajeeha, O'Dea, Anne, Kaklamani, Virginia, Silber, Andrea L M, Flaum, Lisa E, Andreopoulou, Eleni, Wendt, Albert G, Carney, Jennifer F, Sharma, Priyanka, Gralow, Julie R, Lew, Danika L, Barlow, William E, Hortobagyi, Gabriel N

“…Phosphatidylinositol 3-kinase/AKT-serine threonine kinase/mammalian target of rapamycin (mTOR) pathway abnormalities contribute to endocrine resistance…”
Get full text

Abstract GS1-07: Results from a phase III randomized, placebo-controlled clinical trial evaluating adjuvant endocrine therapy +/- 1 year of everolimus in patients with high-risk hormone receptor-positive, HER2-negative breast cancer: SWOG S1207 by Chavez, Marianna, Miao, Jieling, Pusztai, Lajos, Goetz, Matthew P., Rastogi, Priya, Ganz, Patricia A., Mamounas, Eleftherios (Terry), Paik, Soonmyung, Bandos, Hanna, Razaq, Wajeeha, O’Dea, Anne, Kaklamani, Virginia, Silber, Andrea L.M., Flaum, Lisa E., Andreopolu, Eleni, Baar, Joseph, Wendt, Albert G., Carney, Jennifer F., Sharma, Priyanka, Gralow, Julie R., Lew, Danika L., Barlow, William E., Hortobagyi, Gabriel N.

“…BACKGROUND: Abnormalities of the PI3kinase/AKT/mTOR signaling network are common in breast cancer (BC) and are associated with endocrine resistance…”
Get full text